NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Genoskin

Genoskin

Private
ToulouseHealthcare & Life Scienceshttps://genoskin.com/

Last Round

Series A

Sep 16, 2025

Total Funding Raised

$10.34M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Genoskin is a biotechnology company that provides ready-to-use, live human skin models for pharmaceutical, cosmetic, and chemical product testing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

ex vivo skinhuman skin modelspreclinical testinganimal-free testingcontract research organizationCROtoxicology testingefficacy testinghuman tissue modelsin vitro alternativesNAMsnew approach methodologiesspatial biologydrug discoverybiotech research tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Genoskin Comps

Public and private peers based on sector, stage, and business model.

Genoskin comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Genoskin Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 16, 2025
DebtSep 16, 2025
GrantOct 28, 2020
GrantAug 29, 2019
GrantMar 7, 2018
Early Funding
Aug 29, 2017

Key People

Founding team and executive leadership

Pascal Descargues

Founder And CEO, CEO

Founding Team

Frederick Roques

Chief Financial Officer

Executive Team

Claire Jardet

Chief Operating Officer

Executive Team

Genoskin Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Fabrice Bouteille appointed to strengthen governance.

  • Sep 16, 2025

    $9M round completed.

Genoskin Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Genoskin Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Genoskin's valuation, stock price, and market status.

Firmographic Details

HeadquartersToulouse
Employee Range59
Year Founded2011
Last FundingSep 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.